As of: September 15, 2026 (ET)
Disclosure: Dose Digest may have a financial affiliation with telehealth programs in the GLP-1 category. Affiliation does not purchase a higher ranking. Educational journalism, not medical advice.
Reuters reported that in March 2026 the FDA issued warning letters to 30 telehealth companies over misleading marketing of compounded GLP-1 drugs. Some firms allegedly implied compounded products were the same as approved drugs.
Why rules shifted
Brand semaglutide and tirzepatide can be costly without coverage. During official shortages, regulators allowed broader compounding. Stanford Medicine notes tirzepatide left the shortage list in December 2024 and semaglutide in February 2025, removing the main justification for large-scale copies. Clinicians have raised concerns about unapproved forms, additives, dosing errors, and shipping stability.
What a warning letter means
It alleges violations and requests a response. It is not automatically a consumer star rating, a finding that every patient was harmed, or an instant ban. It signals that claims such as “same as” or “generic” drew federal attention.
Questions for shoppers
- Is the offer FDA-approved, compounded, or both?
- Does the site claim identicality?
- Which licensed pharmacy fills it?
- Are membership and medication costs separated?
- Who monitors side effects?
Bring questions to a licensed clinician; do not stop prescribed therapy without guidance.
Bottom line: Compounded GLP-1 marketing is under scrutiny. Confirm claims on current FDA pages and program terms.
Medical disclaimer: Educational only, not medical advice. Dose Digest is not a medical provider.